An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
Background Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary progressive (ORATORIO) multiple sclerosis (MS). These effects may be particularly important among patients with increased disab...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publishing
2020-03-01
|
| coleção: | Multiple Sclerosis Journal - Experimental, Translational and Clinical |
| Acesso em linha: | https://doi.org/10.1177/2055217320911939 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|